RecruitingNot ApplicableNCT07009327

Efficacy and Safety of Photodynamic Therapy for CIN3

Efficacy and Safety of Photodynamic Therapy for Cervical Intraepithelial Neoplasia 3(CIN3):A Multicenter Prospective Cohort Study


Sponsor

Peking University Third Hospital

Enrollment

100 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To investigate the efficacy and safety of photodynamic therapy (20% 5-amino-ketovalerate 630nm red light) in the treatment of cervical intraepithelial neoplasia 3(CIN 3)in women in the real world


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing photodynamic therapy (a treatment using light-activated medication) as a way to treat a pre-cancerous cervical condition called CIN3 — a severe abnormality of cervical cells that, if untreated, could develop into cervical cancer. **You may be eligible if...** - You have been diagnosed with CIN3 (severe cervical cell changes) - Your abnormal area can be fully seen during a colposcopy exam - The abnormal area is in a type 1 or type 2 transformation zone (a specific location on the cervix) **You may NOT be eligible if...** - Your doctor suspects or has confirmed cervical cancer - Your most recent cervical smear (TCT) showed high-grade abnormality - The abnormality involves glandular cells inside the cervix - You have a condition called porphyria or are sensitive to light therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREALA-PDT

use ALA\_PDT to treat the disease


Locations(1)

Peking Unniversity Third Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07009327


Related Trials